Preeclampsia
Conditions
Keywords
preeclampsia
Brief summary
Women who develop preeclampsia during pregnancy are four times more likely to develop cardiovascular disease later in life, even if they are otherwise healthy. The reason why this occurs may be related to lasting blood vessel damage after the pregnancy but there are currently no specific treatment strategies to prevent this disease progression. This study addresses this public health issue by examining whether starting low dose aspirin therapy after pregnancy is an effective treatment for lasting blood vessel damage in order to inform better clinical management of cardiovascular disease risk in women who have had preeclampsia.
Interventions
DRUGAspirin
162mg aspirin capsule
DRUGPlacebo
placebo capsule
Sponsors
Anna Stanhewicz, PhD
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Masking description
double blind
Eligibility
Sex/Gender
FEMALE
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
* had preeclampsia in the past 5 years, * 18 years or older
Exclusion criteria
* current daily aspirin use, * skin diseases, * current tobacco or nicotine use (including vaping), * diagnosed or suspected hepatic or metabolic disease including chronic kidney disease (CKD) defined as reduced eGFR \< 60 mL/min/1.73m2, * statin or other cholesterol-lowering medication, * current antihypertensive medication, * history of hypertension prior to pregnancy, * history of gestational diabetes, * currently pregnancy, * body mass index \<18.5 kg/m2, * allergy to materials used during the experiment.(e.g. latex), * known allergies to study drugs, * bleeding disorders, peptic ulcer disease, gastritis, GI bleeding and gastroesophageal reflux disease (GERD).
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| magnitude of microvascular endothelial function | baseline, 12 weeks | skin blood flow response to acetylcholine delivered via intradermal microdialysis |
| magnitude of brachial artery endothelial function | baseline, 12 weeks | brachial artery flow mediated dilation |
| magnitude of microvascular endothelin-1 mediated constriction | baseline, 12 weeks | skin blood flow response to endothelin-1 delivered via intradermal microdialysis |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| magnitude of microvascular nitric oxide-dependent dilation | baseline, 12 weeks | skin blood flow response to acetylcholine + L-NAME delivered via intradermal microdialysis |
Countries
United States
Contacts
Primary ContactAnna Reid-Stanhewicz, PHD
Outcome results
None listed